Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived mesenchymal stem cells in end-stage renal disease before kidney transplantation
NL-OMON34665Phase 1Withdrawn
- Sponsor
- Erasmus MC
- Start
- Jan 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1 trial of autologous adipose-derived mesenchymal stromal cells in end-stage kidney disease (ESKD) (4 arms), sponsored by Erasmus MC. Primary endpoints: Safety and Feasibility. Planned start Jan 2011; status: withdrawn.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON34665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34665.